Janssen, Araxes collaborate on cancer drug development

02/28/2013 | Genetic Engineering & Biotechnology News

Janssen Biotech and Araxes Pharma agreed to work on oncology drugs against a certain target. Araxes, which will be initially in charge of development, will receive an upfront fee, research funding, milestone fees and sales royalties. Janssen will get the rights to market the products arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID